Combination treatment of both chemotherapy-sensitive and chemotherapy-refractory ovarian cancer cell lines with inhibitors of menin and DOT1L further reduced proliferation compared to treatment with either inhibitor alone [301]. This evidence concerns the gene MEN1 and ovarian cancer.